Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors
Vivo Capital Closes $1.43 Billion Fund IX to Invest in Healthcare and Life Science Companies
Vivo Capital Closes $1.43 Billion Fund IX to [...]
12 VCs who matter in biotech, but you never read about
12 VCs who matter in biotech, but [...]
Swift Health Systems Raises $45 Million in Series C Funding
Swift Health Systems Raises $45 Million in [...]
AtriCure Enters Into Definitive Agreement to Acquire SentreHEART
AtriCure Enters Into Definitive Agreement to Acquire [...]
Vivo Capital to Sponsor New Frontier Corporation’s Acquisition of United Family Healthcare
Vivo Capital to Sponsor New Frontier Corporation’s [...]
Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis
Menlo Therapeutics’ Successful Phase 2 Clinical Trial [...]
Impel NeuroPharma Closes $67.5 Million Series D Financing
Impel NeuroPharma Closes $67.5 Million Series D [...]
-
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of MigraineBiohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
Biohaven Delivers Positive Phase 3 Results with [...]
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals [...]